Avera Names Myles Greenberg, MD, as CEO of Alucent Medical

This Week’s News in Review

This Week's News in Review! Medical Device News Magazine keeps our readers up-to-date on breaking industry news! Learn how Medical Device News Magazine can help...

New Research Shows Nearly Half of Elderly Suffer Decreased Mobility During Lockdown

In a survey of UK adults with parents over the age of 75, while over half (52%) of respondents remain worried about their parents catching Covid, 48 percent are concerned about parental loneliness, and 46 percent about their parents falling alone and not being able to get up or get help. This figure remained high even among those whose parents are in care homes, with 37% of respondents still most concerned about parents falling over.

American College of Cardiology Names Ravee Kurian COO/CFO

Kurian comes to ACC following a 20-year stint at Publicis Sapient, a leading technology and communications consultancy, where he led critical and sensitive digital transformation initiatives for Fortune 500 and U.S. federal clients.

 

“NVS Therapy has the potential to dramatically improve the care of patients suffering from debilitating peripheral vascular disease, and I look forward to being a part of the team advancing this groundbreaking technology into patient treatment,” Dr. Greenberg said.

Myles D. Greenberg, MD, was named President and CEO of Alucent Medical, Inc., a new company licensed to develop a novel drug/device combination therapy for the treatment of peripheral vascular disease (PVD). The treatment, Natural Vascular Scaffolding (NVS)TM, has recently gained FDA approval to move forward with Phase 1 human clinical trials.

Alucent is owned by the research and development arm of Avera Health, based in Sioux Falls, S.D.

NVS combines percutaneous balloon angioplasty (PTA) with a novel drug that builds natural scaffolding to keep the vessel open, potentially replacing the need for a stent. Current therapies such as PTA and implanted stents can result in recurrence of the vascular lesion, requiring the need for retreatment. Avera scientists developed this product under the leadership of Ron Utecht, PhD.

“NVS Therapy has the potential to dramatically improve the care of patients suffering from debilitating peripheral vascular disease, and I look forward to being a part of the team advancing this groundbreaking technology into patient treatment,” Dr. Greenberg said.

Dr. Greenberg brings to Alucent Medical, Inc. extensive experience in life-sciences related business and new product development, having served as a partner in early-stage health care venture capital firms HealthInvest Equity Partners and CHL Medical Partners based in Stamford, Conn., and as an active director of many companies developing novel medical devices, biopharmaceuticals and health care technologies.

Prior to his career in venture capital, Dr. Greenberg was an academic emergency physician and hospital administrator at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Mass. He holds a bachelor of applied science degree from the University of Pennsylvania School of Engineering and Applied Science; doctor of medicine degree from Yale University School of Medicine; and master of business administration from Harvard University Graduate School of Business Administration.

“Dr. Greenberg’s experience and knowledge of the biotechnology landscape will guide us through the crucial next steps of development,” said Dave Kapaska, DO, Regional President and CEO of Avera McKennan Hospital & University Health Center. “Avera has been supporting and investing in the research and development of this product since its inception, and with his leadership, we can realize its potential.”

“With his years of experience helping early-stage companies develop new medical technologies, Dr. Greenberg is the right person to move Alucent forward toward successful clinical trials and eventual marketing,” said James Corbett, Chairman of the Alucent Board of Directors. “We look forward to the successful development of this important new therapy for patients.”

About Alucent Medical, Inc.

Alucent Medical Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah. Alucent Medical was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS), a novel combination drug-device product for the treatment of patients suffering from peripheral vascular disease. Alucent Medical is currently conducting U.S. phase 1 human clinical trials. Visit alucentmedical.com for more information.

spot_img

DON'T MISS

Dr Jonathan Slotkin Appointed to Peer Well Board of Directors

Alongside the appointment, PeerWell is launching its new clinical practice, PeerWell Health.

Zimmer Biomet Announces New Appointments to Executive Leadership Team

Wilfred van Zuilen Appointed as President of Europe, Middle East and Africa. Nitin Goyal, M.D. Appointed to Newly Created Role of Chief Science, Technology and Innovation Officer.

Subscribe to Medical Device News Magazine here.

Related Articles